未经批准:目前,由于儿童常规免疫接种产生的间接影响,成人接种23价肺炎球菌多糖疫苗(PPsV23)和/或13价肺炎球菌结合疫苗(PCV13)的临床获益尚不确定.这项研究调查了PPsV23/PCV13在PCV13免费(公共资助)批准婴儿后2年早期预防加泰罗尼亚成年人肺炎的临床有效性。
UNASSIGNED:我们进行了一项基于人群的队列研究,涉及加泰罗尼亚≥50岁的2,059,645名成年人。西班牙,在2017/01/2018/31/12之间随访。主要结局为肺炎球菌肺炎(PP)或全因肺炎(ACP)住院,主要解释变量为PCV13/PPsV23疫苗接种状态。Cox回归模型用于评估按年龄/性别和潜在风险条件调整的疫苗接种有效性。
未经评估:队列成员被跟踪了3,958,528人年(32,328接种PCV13疫苗,1,532,186PPsV23疫苗接种),观察3592PP(接种PCV13的131对接种PPsV23的2476)和24,136ACP(接种PCV13的876对接种PPsV23的17,550)。PP的发病率(每100,000人年)为90.7(PCV13疫苗接种中的394.2与PPsV23疫苗接种中的161.6)和ACP的609.7(PCV13疫苗接种中的2636.3与PPsV23疫苗接种中的1145.4)。PCV13与PP(危险比[HR]:1.24;95%CI:1.00-1.52;p=0.046)和ACP(HR:1.38;95%CI:1.28-1.49;p<0.001)的风险增加相关,而PPsV23没有改变PP的风险(HR:1.07;95%CI:0.98-1.18;p=0.153),并且略微增加了ACP:1.14的风险在侧重于风险个体的补充分析中(即,老年人,免疫损害和其他慢性疾病)疫苗接种的保护作用也没有出现。
UNASSIGNED:数据不支持肺炎球菌疫苗(或PCV13或PPsV23)在目前的PCV13儿童普遍免疫接种时代对加泰罗尼亚中老年人肺炎的临床益处。非常需要新的扩展价PCV。
UNASSIGNED: At present, because of indirect effects derived from routine childhood immunisation, clinical benefits vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPsV23) and/or the 13-valent pneumococcal conjugate vaccine (PCV13) are uncertain. This study investigated clinical effectiveness for both PPsV23/PCV13 in preventing pneumonia among Catalonian adults during an earlier 2-year period post-PCV13 free (publicly funded) approval for infants.
UNASSIGNED: We conducted a Population-based cohort study involving 2,059,645 adults ≥ 50 years in Catalonia, Spain, who were followed between 01/01/2017-31/12/2018. Primary outcomes were hospitalisation from pneumococcal pneumonia (PP) or all-cause pneumonia (ACP) and main explanatory variable was PCV13/PPsV23 vaccination status. Cox regression models were used to estimate vaccination effectiveness adjusted by age/sex and underlying-risk conditions.
UNASSIGNED: Cohort members were followed for 3,958,528 person-years (32,328 PCV13-vaccinated, 1,532,186 PPsV23-vaccinated), observing 3592 PP (131 in PCV13-vaccinated vs 2476 in PPsV23-vaccinated) and 24,136 ACP (876 in PCV13-vaccinated vs 17,550 in PPsV23-vaccinated). Incidence rates (per 100,000 person-years) were 90.7 for PP (394.2 in PCV13-vaccinated vs 161.6 in PPsV23-vaccinated) and 609.7 for ACP (2636.3 in PCV13-vaccinated vs 1145.4 in PPsV23-vaccinated). The PCV13 was associated with an increased risk of PP (hazard ratio [HR]: 1.24; 95% CI: 1.00-1.52; p = 0.046) and ACP (HR: 1.38; 95% CI: 1.28-1.49; p < 0.001) whereas the PPsV23 did not alter the risk of PP (HR: 1.07; 95% CI: 0.98-1.18; p = 0.153) and slightly increased the risk of ACP (HR: 1.14; 95% CI: 1.10-1.18; p < 0.001). In supplementary analyses focused on at-risk individuals (i.e., elderly persons, immunocompromissing and other chronic illnesses) protective effects of vaccination did not emerge either.
UNASSIGNED: Data does not support clinical benefits from pneumococcal vaccination (nor PCV13 neither PPsV23) against pneumonia among Catalonian middle-aged and older adults in the current era of universal PCV13 childhood immunisation in our setting. New extended valency PCVs are greatly needed.